Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis.
Histamine H2-receptor antagonists are moderately effective in symptomatic treatment and healing of erosive oesophagitis, but they are not as effective as the proton pump inhibitor omeprazole. In some studies prokinetic agents seem to increase the effectiveness of H2-antagonists, but no study comparing the efficacy of omeprazole to H2-antagonists plus prokinetic agents has been performed. The purpose of this study was to compare the efficacy and tolerability of 20 mg omeprazole daily with 150 mg ranitidine b.d.s. plus the prokinetic agent 10 mg metoclopramide q.d.s. in patients with erosive oesophagitis. After both 4 and 8 weeks of treatment, omeprazole healed the mucosa in significantly more patients than did ranitidine plus metoclopramide. Omeprazole also provided significantly greater relief from daytime heartburn, nighttime heartburn, and acid regurgitation, and was associated with decreased concomitant antacid use. Although the overall incidence of adverse events was similar in the two treatment groups, a significantly higher number of treatment-related adverse events and more treatment-related withdrawals from the study occurred in the ranitidine plus metoclopramide treatment group. Omeprazole is more effective and better tolerated than the combination of standard dose ranitidine plus metoclopramide for patients with erosive oesophagitis.
Robinson
M
M
Oklahoma Foundation for Digestive Research, Oklahoma City 73104.
Decktor
D L
DL
Maton
P N
PN
Sabesin
S
S
Roufail
W
W
Kogut
D
D
Roberts
W
W
McCullough
A
A
Pardoll
P
P
Saco
L
L
D000328:Adult; D000863:Antacids / Q000627:therapeutic use; D002940:Circadian Rhythm / Q000502:physiology; D004359:Drug Therapy, Combination; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006356:Heartburn / Q000188:drug therapy; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D011899:Ranitidine / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000863:Antacids; D011899:Ranitidine; D009853:Omeprazole; D008787:Metoclopramide